Akeso to Share Global Strategy for New Drug Development at the 43rd J.P. Morgan Healthcare Conference

Newest

2025 CCBEC Shenzhen Cross-Border E-Commerce Exhibition Grand Opening Next Week, Puff Media Joins Hands with CCBEC to Decode New Global Market Opportunities
fire breaks out in central paris restaurant amid violent nationwide protests
what could trigger nato article 5 after poland shoots down russian drones?
inside camp where dad hid kids for years before being shot dead by new zealand police

Links

Akeso to Share Global Strategy for New Drug Development at the 43rd J.P. Morgan Healthcare Conference

2025-01-08 Akeso, Inc. HaiPress

HONG KONG and SAN FRANCISCO,Jan. 7,2025 -- Akeso,Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce its participation in the upcoming 43rd Annual J.P. Morgan Healthcare Conference,taking place on January 13,2025,in San Francisco,California. The company's founder,chairwoman,president,and CEO,Dr. Michelle Xia will share the latest developments and plans for its globally leading programs,including ivonescimab (PD-1/VEGF bispecific antibody),cadonilimab (PD-1/CTLA-4 bispecific antibody),and ligufalimab (CD47 monoclonal antibody),as well as more cutting-edge multispecific antibody pipeline assets.

Time：SF local time 2:15-2:55pm,Jan. 15,2025

About Akeso

Akeso (HKEX: 9926.HK) is a leading biopharmaceutical company committed to the research,development,manufacturing and commercialization of the world's first or best-in-class innovative biological medicines. Founded in 2012,the company has created a unique integrated R&D innovation system with the comprehensive end-to-end drug development platform (ACE Platform) and bi-specific antibody drug development technology (Tetrabody) as the core,a GMP-compliant manufacturing system and a commercialization system with an advanced operation mode,and has gradually developed into a globally competitive biopharmaceutical company focused on innovative solutions.With fully integrated multi-functional platform,Akeso is internally working on a robust pipeline of over 50 innovative assets in the fields of cancer,autoimmune disease,inflammation,metabolic disease and other major diseases. Among them,22 candidates have entered clinical trials (including 11 bispecific/multispecific antibodies and bispecific antibody-drug conjugates). Additionally,5 new drugs are commercially available,and 5 new drugs across 7 indications are currently under regulatory review for approval. Through efficient and breakthrough R&D innovation,Akeso always integrates superior global resources,develops the first-in-class and best-in-class new drugs,provides affordable therapeutic antibodies for patients worldwide,and continuously creates more commercial and social values to become a global leading biopharmaceutical enterprise.

For more information,please visithttps://www.akesobio.com/en/about-us/corporate-profile/ and follow us on Linkedin,andX .

Disclaimer: This article is reproduced from other media. The purpose of reprinting is to convey more information. It does not mean that this website agrees with its views and is responsible for its authenticity, and does not bear any legal responsibility. All resources on this site are collected on the Internet. The purpose of sharing is for everyone's learning and reference only. If there is copyright or intellectual property infringement, please leave us a message.